Haobam Reena, Sindhu Kizhakke M, Chandra Goutam, Mohanakumar Kochupurackal P
Division of Clinical & Experimental Neuroscience, Indian Institute of Chemical Biology, Calcutta, India.
Behav Brain Res. 2005 Sep 8;163(2):159-67. doi: 10.1016/j.bbr.2005.04.011.
Parkinson's disease (PD) is a common neurodegenerative disease that exhibits motor dysfunctions, such as tremor, akinesia and rigidity. In the present study, we investigated whether swim-test could be used as one of the behavioural monitoring techniques to study motor disability in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in two mouse strains, Balb/c and C57BL/6. Mice were treated with different doses of MPTP (10, 20 and 30 mg/kg, twice, 16 h apart), and were subjected to swim-test on the third day of the first MPTP injection. MPTP-induced tremor was monitored at 30 min, and akinesia and rigidity developed were studied 3 h after the second MPTP treatment. While tremor and akinesia produced were dose-dependent and the intensity of tremor was comparable in the two strains of mice studied, the latter response in C57BL/6 was significantly lesser than that observed in Balb/c. Rigidity exhibited in Balb/c mice were dose-dependent, but not in C57BL/6. There was observed an inverse relationship between swim-score and the doses of MPTP in both the strains. MPTP caused a significant and dose-dependent reduction in striatal dopamine level in both the strains of mice, when assayed on the fourth day employing an HPLC with electrochemical detector. A significant positive correlation existed (r = 0.94 for Balb/c and r = 0.82 for C57BL/6) for the striatal dopamine-depletion and the swim-score in the MPTP-treated mice. While swim deficit and striatal dopamine loss were long lasting (till the third week) in C57BL/6, in Balb/c mice the motor deficit showed recovery by the second week. In these animals, a significant attenuation in striatal dopamine loss was observed by the third week. These results indicate that swim ability is directly proportional to striatal dopamine content, and suggest that swim-test could be used as a major technique to monitor motor dysfunction in experimental animals.
帕金森病(PD)是一种常见的神经退行性疾病,表现出运动功能障碍,如震颤、运动不能和僵硬。在本研究中,我们调查了游泳测试是否可以作为一种行为监测技术,用于研究1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)诱导的两种小鼠品系(Balb/c和C57BL/6)帕金森综合征中的运动功能障碍。小鼠接受不同剂量的MPTP(10、20和30mg/kg,分两次给药,间隔16小时),并在首次注射MPTP的第三天进行游泳测试。在30分钟时监测MPTP诱导的震颤,并在第二次MPTP治疗后3小时研究运动不能和僵硬的发展情况。虽然产生的震颤和运动不能呈剂量依赖性,且在所研究的两种小鼠品系中震颤强度相当,但C57BL/6中的后一种反应明显小于Balb/c中观察到的反应。Balb/c小鼠中表现出的僵硬呈剂量依赖性,但C57BL/6中并非如此。在两种品系中均观察到游泳评分与MPTP剂量之间呈负相关。当在第四天使用带有电化学检测器的高效液相色谱法进行测定时,MPTP在两种小鼠品系中均导致纹状体多巴胺水平显著且呈剂量依赖性降低。在MPTP处理的小鼠中,纹状体多巴胺耗竭与游泳评分之间存在显著正相关(Balb/c中r = 0.94,C57BL/6中r = 0.82)。虽然游泳缺陷和纹状体多巴胺损失在C57BL/6中持续时间较长(直至第三周),但在Balb/c小鼠中,运动功能缺陷在第二周时显示恢复。在这些动物中,到第三周时观察到纹状体多巴胺损失显著减轻。这些结果表明游泳能力与纹状体多巴胺含量成正比,并表明游泳测试可作为监测实验动物运动功能障碍的主要技术。